Groundbreaking
COVID-19 Pathogen Adsorption Therapy
ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter is a groundbreaking hemoperfusion technology that addresses unmet clinical needs for treating severe COVID-19.
An Exciting Option for Critical Care Teams
The Seraph 100 uses microbead adsorption media with chemically-bonded heparin to mimic the binding sites that COVID-19 uses when they invade the bloodstream. COVID-19 is removed from the bloodstream, and once bound, remains in the filter.
Patients Tell Their Stories
Extracorporeal—meaning outside the body—blood purification treatments are usually reserved for the severely or critically ill patient. Learn more about how Seraph 100 is used to treat COVID-19.
In the News
See what’s happening at ExThera Medical and recent updates about the Seraph 100 and ONCOBind.
ExThera Medical Taps Current Board Member and Top Finance Executive to Take the Helm
ExThera Medical Awarded U.S. Federal Supply Schedule Contract for Seraph 100 Blood Filter
FDA Grants ExThera Multiple Breakthrough Device Designations for its Seraph® 100 Filter
ExThera Medical Receives Certification for Medical Device Single Audit Program (MDSAP) and Recertification for International Organization for Standardization for Medical Devices (ISO 13485)
MM0001 Rev A